On heels of landmark approval, Bristol Myers Squibb embarks on billion-dollar oncology deal with metastatic cancer startup

Paul Schloesser

Associate Editor

After the FDA approved BMS’s new LAG-3 oncology drug late last week, Bristol Myers Squibb is diving headfirst into a hyper-niche field of oncology research …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

On heels of landmark approval, Bristol Myers Squibb embarks on billion-dollar oncology deal with metastatic cancer startup

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

FTC to sue major PBMs over insulin rebates, claiming they inflated patient cost

Novo says its CB1 drug helped shed weight, but efficacy and safety questions remain

Biotech VC firm outlines plans for $100M fund

Sanofi's BTK inhibitor again slows MS progression, but liver enzymes continue to be tricky

Lexicon's president to step down as decision date looms; Sarepta welcomes Lilly, GSK vet to board

Breaking down silos with a new quantitative approach to drug development

On heels of land­mark ap­proval, Bris­tol My­ers Squibb em­barks on bil­lion-dol­lar on­col­o­gy deal with metasta­t­ic can­cer start­up

Associate Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

On heels of landmark approval, Bristol Myers Squibb embarks on billion-dollar oncology deal with metastatic cancer startup